• Anotherway

  Participated · Equity · Oct 2023

  Anotherway, founded in 2018 by Samuel Olichon and based in Marseille, develops zero-waste household and personal-care products. The company launched with a Bee Wrap and now offers a catalogue of 25 products across hygiene, kitchen and home-care categories, selling about 300,000 units over four years. Production is positioned in Europe (100%), with 75% made in France and 36% made locally in Marseille, and the company holds B Corp certification. Anotherway is already distributed in roughly 1,000 retail points including Biocoop, Marcel & Fils, Bio c’bon and So bio, and plans to enter the grande distribution via the Ya.qa brand in November. The team comprises 24 employees; the recent financing is intended to fund product development, expand retail distribution and continue commercialization. Future plans include moving textile production fully to France and switching to glass containers for its packaging.

• Provepharm life Solutions

  Participated · Equity · Sep 2021

  Provepharm Life Solutions identifies new therapeutic uses for mature molecules, with a focus on antidotes and surgical dyes. Its platform redefines purity requirements for active ingredients to maximize therapeutic potential and explore untouched indications. The company developed a patented synthesis method for methylene blue, enabling marketing authorizations in more than 30 countries. Provepharm is using recent funding to hire staff in France and the United States and to expand its laboratories in Marseille. The firm is headquartered in Marseille with an operation in Philadelphia, employs over 90 people, and reported turnover of €48.5m in 2020. It was founded in 1998 and is led by CEO Michel Feraud. Provepharm Life Solutions is an independent pharmaceutical and life‑sciences group created in 1998 and based in Marseille, France. The company provides pharmaceutical‑grade methylene blue in 25 countries and focuses on revitalizing known molecules. Its strategy is to develop its product range, apply its expertise to other molecules, and strengthen its international business. Provepharm ended 2018 with record results and completed its first company acquisition in October 2018, integrating a new product portfolio. Over the next months the company plans to accelerate growth and strengthen its US subsidiary to expand its international presence.

No current team members are available.